Print Page     Close Window     

SEC Filings

10-K/A
BIOTIME INC filed this Form 10-K/A on 04/02/2018
Entire Document
 
 

 

ONCOCYTE CORPORATION

BALANCE SHEETS

(In thousands)

 

   December 31, 
   2017   2016 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $7,600   $10,174 
BioTime shares held as available-for-sale securities, at fair value   760    2,237 
Prepaid expenses and other current assets   168    285 
Total current assets   8,528    12,696 
           
NONCURRENT ASSETS          
Intangible assets, net   746    988 
Equipment and furniture, net   822    688 
Deposits   120    75 
TOTAL ASSETS  $10,216   $14,447 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Amount due to BioTime and affiliates  $2,099   $2,854 
Accounts payable   175    422 
Accrued expenses and other current liabilities   1,042    797 
Loan payable, current   800    - 
Capital lease liability, current   338    202 
Total current liabilities   4,454    4,275 
           
LONG-TERM LIABILITIES          
Loan payable, net of deferred financing costs, noncurrent   1,070    - 
Capital lease liability, noncurrent   289    310 
TOTAL LIABILITIES   5,813    4,585 
           
Commitments and contingencies (see Note 9)          
           
STOCKHOLDERS’ EQUITY          
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding   -    - 
Common stock, no par value, 50,000 shares authorized; 31,452 and 28,737 shares issued and outstanding at December 31, 2017 and 2016, respectively   59,968    45,818 
Accumulated other comprehensive loss on available-for-sale securities   (888)   (654)
Accumulated deficit   (54,677)   (35,302)
Total stockholders’ equity   4,403    9,862 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $10,216   $14,447 

 

The accompanying notes are an integral part of these financial statements.

 

   

© Copyright BioTime, Inc.